NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. Continue reading below

Resources and Financial Support

$0 Co-Pay* for eligible patients

Up to $25,000 per year and no monthly cap per patient

Currently $0 Co-Pay is available through REACH, specialty pharmacy providers (SPPs), and online

  • Only privately insured patients who were not previously enrolled in the REACH Commercial Co-Pay Assistance Program are eligible for this program
  • Patients enrolled in Medicare, Medicaid, or any government-funded programs are not eligible for $0 Co-Pay assistance
  • If ineligible, a REACH counselor will refer patients to independent charitable organizations to assist with out-of-pocket costs
  • If prior authorization determination is delayed or denied, patients will be assessed for temporary patient assistance
$0 Co-Pay Assistance-A New Level of Support

There are 3 easy ways to help privately insured patients get $0 Co-Pay

Enroll Online

Nexavar Adverse Reactions Chart
RX Pad Image
Nexavar (sorafenib) Pill Bottle
  • Enroll

    Enter patient information to
    instantly obtain BIN & Group #
RX Pad Image
AE Grade Scale Images
  • Use

    Add as secondary payer for
    immediate coverage
Enroll Now

For more information on enrolling online, call 1–866–581–4992AM–5 PM EST/EFT

Enroll in REACH

Call 1–866–639–2827 to speak to a service counselor

Contact SPPs

Select from our list of specialty pharmacy providers

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, and may not participate if this program is prohibited by or conflicts with their private insurance policy, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer′s Patient Assistance Program are not eligible. Bayer may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of the REACH program at any time, including but not limited to this commercial co-pay assistance program.

REACH offers referrals to third party organizations; eligibility criteria apply.


NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Important Safety Information

For important risk and use information about NEXAVAR, please see the full Prescribing Information.


For important risk and use information about STIVARGA, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.